Affiliation:
1. Universitas YARSI
2. Universitas Indonesia
3. National Cancer Center Dharmais Hospital
4. Universitas Padjajaran
Abstract
Background. Curcumin is a polyphenol that has pharmacological activity that can inhibit tumor cell growth and induce apoptosis through various mechanisms. However, the specifc mechanism of curcumin cytotoxicity remains controversial because of many anti- and pro-apoptotic signaling pathways in various cell types.This study aims to examine the relationship among curcumin on RASSF1A, Bax protein levels, and caspase-3 activity in supporting the apoptotic mechanism in CSA03 breast cancer cells.Material and Methods. Curcumin administration to cancer cells is based on differences in dosage with 24-hour incubation. Cytotoxicity after curcumin administration was determined using MTS. RASSF1A and Bax protein levels were tested through ELISA. Caspase-3 activity was used to determine apoptosis and was tested using fow cytometry.Results. The results indicated that curcumin had a cytotoxicity effect of 40.85 µg/mL. At concentrations of 40 µg/mL and 50 µg/mL, curcumin increases levels of protein RASSF1A (∆ = 26.53% and 47.35%, respectively), Bax (∆ = 48.79% and 386.15%), and caspase-3 (∆ = 1,678.51% and 1,871.889%) signifcantly.Conclusions. Curcumin exhibits anti-proliferative activity and apoptotic (Caspase-3) effects through activation of RASSF1A and Bax.
Publisher
Tomsk Cancer Research Institute
Reference23 articles.
1. 1.World Health Organization. Breast cancer-WHO [Internet]. URL: https://www.who.int/news-room/fact-sheets/detail/breast-cancer [cited 2022 Jul 22].
2. Kanker di Indonesia tahun 2010: Data Histopatologik. Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Indonesia dan Yayasan Kanker Indonesia.
3. Abdulkareem I.H., Zurmi I.B. Review of hormonal treatment of breast cancer. Niger J Clin Pract. 2012; 15(1): 9–14. doi: 10.4103/1119- 3077.94088.
4. Thuy L.H.A., Thuan L.D., Phuong T.K. DNA hypermethylation in breast cancer. In: Pham PV, ed. (2017) Breast Cancer – From Biology to Medicine. London: InTech. 147–61. doi: 10.5772/66900.
5. Cao X., Tang Q., Holland-Letz T., Gündert M., Cuk K., Schott S., Heil J., Golatta M., Sohn C., Schneeweiss A., Burwinkel B. Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals. Int J Mol Sci. 2018; 19(3): 900. doi: 10.3390/ijms19030900.